

A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects with Chronic Hepatitis B Infection

Published: 25-05-2016

Last updated: 17-04-2024

The primary objective of this Registry is: *To evaluate the long term effects of Hepatitis B Virus (HBV) treatment of the parental study on the HBV serologic changes through Week 144
The secondary objective of this Registry is : *To evaluate the long...

| | |
|------------------------------|----------------------------|
| Ethical review | Approved WMO |
| Status | Pending |
| Health condition type | Viral infectious disorders |
| Study type | Observational invasive |

Summary

ID

NL-OMON43924

Source

ToetsingOnline

Brief title

GS-US-330-1508

Condition

- Viral infectious disorders

Synonym

Chronic Hepatitis B, inflammation of liver

Research involving

Human

Sponsors and support

Primary sponsor: Gilead Sciences, Inc

Source(s) of monetary or material Support: Gilead Sciences Inc.

Intervention

Keyword: Chronic Hepatitis B, Long Term Follow-up Registry

Outcome measures

Primary outcome

The primary endpoints of this Registry are:

*For subjects who are HBsAg positive at Baseline:

The proportion of subjects with serum HBsAg decline $\geq 0.5 \log_{10}$ IU/ml from Baseline at Week 48

*For subjects who are HBsAg negative at Baseline:

The proportion of subjects who remain HBsAg negative at Week 48

Secondary outcome

The secondary endpoints of this Registry are:

*For subjects who are HBsAg positive at Baseline:

The proportion of subjects with serum HBsAg decline $\geq 0.5 \log_{10}$ IU/ml from Baseline at Week 144

The proportion of subjects who achieve HBsAg loss at Weeks 48 and 144

*For subjects who are HBsAg negative at Baseline:

The proportion of subjects who remain HBsAg negative at Week 144

*For subjects HBeAg positive at Baseline:

proportions of subjects with HBeAg loss and seroconversion at Week 48

proportions of subjects with HBeAg loss and seroconversion at Week 144

*For HBeAg positive subjects who achieved HBeAg seroconversion during the parental study:

proportions of subjects who remain HBeAg negative and HBeAb positive at
Week 48-proportions of subjects who remain HBeAg negative and HBeAb positive at
Week 144

*For subjects on treatment with OAV anti-HBV, the proportion of subjects with
HBV-DNA < LLOQ at Weeks 48, 96 and 144

The change from Baseline in HBV DNA at Weeks 48, 96, and 144

The exploratory endpoints of this Registry are:

*For subjects on treatment with OAVs anti-HBV, the proportion of subjects with
HBV DNA < LLOQ target detected and proportion of subjects with HBV DNA < LLOQ
target not detected, at Weeks 48, 96 and 144

*Quality of Life measures in subjects who achieve HBsAg loss and in subjects
who do not achieve HBsAg loss

Study description

Background summary

See protocol page 10, 1.1 Background

Study objective

The primary objective of this Registry is:

*To evaluate the long term effects of Hepatitis B Virus (HBV) treatment of the
parental study on the HBV serologic changes through Week 144

The secondary objective of this Registry is :

*To evaluate the long term effects of HBV treatment of the parental study on
changes in HBV DNA levels through Week 144

The exploratory objective of this Registry is:

*To assess quality of life following treatment in a Gilead sponsored chronic
hepatitis B study.

Study design

This Registry will enroll subjects who were treated in a Gilead sponsored chronic hepatitis B (CHB) study. Subjects who were treated in selected Gilead-sponsored studies for CHB are eligible to participate in this Registry. In order to manage the total study enrollment, Gilead Sciences, Inc. will determine which treatment protocols and sites to include in this Registry study. At its sole discretion, Gilead may at any time discontinue enrollment, suspend screening, and/or early withdraw individual subjects from individual treatment protocols prior to study completion (upon written notice to the site) regardless of the progress or outcome of the protocol assessments performed. Once enrolled, subjects will be followed for up to 144 weeks (three years). A Baseline visit will be scheduled within 120 days from the final visit of the parental protocol, except for subjects from previous Gilead-sponsored study number GS-US-174-0149, who will have up to one year from their last visit in that protocol. Clinic visits will occur at Baseline (Day 1) and at Weeks 12, 24, 48, 72, 96, 120 and 144. For subjects from previous Gilead-sponsored study number GS US 174 0149, a Screening visit is also required to determine eligibility for study participation.

During the Registry, subjects* CHB treatment will be managed per standard of care. Subjects who begin an investigational agent(s) for HBV infection during the course of the Registry will discontinue participation in the Registry.

Intervention

not applicable

Study burden and risks

not applicable

Contacts

Public

Gilead Sciences, Inc

333 Lakeside Drive nap
Foster City, CA 94404
US

Scientific

Gilead Sciences, Inc

333 Lakeside Drive nap
Foster City, CA 94404

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible to participate in the study.

1. Must have participated in a Gilead-sponsored CHB study no more than 120 days prior to Baseline (Day 1), except for subjects from previous Gilead-sponsored study number GS-US-174-0149, who will have up to one year from their last visit in that protocol
2. Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
3. Must be willing and able to comply with the visit schedule and study requirements

For subjects from previous Gilead-sponsored study number GS-US-174-0149, subjects must meet either one of the following inclusion criteria to be eligible to participate in the study:

4. Must have documented HBV DNA < 2,000 IU/mL at time of Screening visit, which shall occur no later than 1 year post last study visit in GS-US-174-0149
5. Must have documented HBsAg negative status anytime during participation in GS-US-174-0149 regardless of ongoing HBV treatment

Exclusion criteria

Subjects who meet any of the following exclusion criteria are not eligible to participate in the study.

1. Participating or plans to participate in another clinical study with an investigational agent
2. History or current presence of clinically-significant illness or any other major medical disorder that may interfere with subject follow-up, assessments or compliance with the protocol.
3. Believed by the Study Investigator to be inappropriate for study participation for any reason not otherwise listed

For subjects from previous Gilead-sponsored study number GS-US-174-0149 meeting Inclusion Criteria #4, subjects who meet the following exclusion criteria are not eligible to participate in the study:

4. Received TDF monotherapy either as part of GS-US-174-0149 Arm C (TDF monotherapy arm) or for TDF retreatment, and have taken any HBV antiviral therapy since completion of GS-US-174-0149

Study design

Design

| | |
|------------------|-------------------------|
| Study phase: | 2 |
| Study type: | Observational invasive |
| Masking: | Open (masking not used) |
| Control: | Uncontrolled |
| Primary purpose: | Other |

Recruitment

| | |
|---------------------------|-------------|
| NL | |
| Recruitment status: | Pending |
| Start date (anticipated): | 30-06-2016 |
| Enrollment: | 7 |
| Type: | Anticipated |

Ethics review

| | |
|--------------|------------|
| Approved WMO | |
| Date: | 25-05-2016 |

| | |
|-----------------------|---|
| Application type: | First submission |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |
| Approved WMO Date: | 16-03-2017 |
| Application type: | Amendment |
| Review commission: | METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam) |

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|--------------------|----------------|
| ClinicalTrials.gov | NCT0225858 |
| CCMO | NL55437.078.16 |